HCV Genotypes, Characterization of Mutations Conferring Drug Resistance to Protease Inhibitors, and Risk Factors among Blood Donors in São Paulo, Brazil by Nishiya, Anna S. et al.
HCV Genotypes, Characterization of Mutations
Conferring Drug Resistance to Protease Inhibitors, and
Risk Factors among Blood Donors in Sa˜o Paulo, Brazil
Anna S. Nishiya1,2*, Cesar de Almeida-Neto1,3, Suzete C. Ferreira1,2, Cecı´lia S. Alencar2,4,
Claudia Di-Lorenzo-Oliveira , Jose5 ´ E. Levi , Nanci A. Salles , Alfredo Mendrone Jr. ,1 1
Ester C. Sabino2,6
1 Fundac¸a˜o Pro´-Sangue/Hemocentro de Sa˜o Paulo, Sa˜o Paulo, Brazil, 2 Infectious Diseases Division (DIPA), Federal University of Sa˜o Paulo, Sa˜o Paulo, Brazil, 3Discipline of
Medical Science, Faculty of Medicine, University of Sa˜o Paulo, Sa˜o Paulo, Brazil, 4 LIM 03 Lab. Medice Laboratory, Department of Pathology, HCFMUSP, Sa˜o Paulo, Brazil,
5University of Sa˜o Joa˜o del-Rei, Divino´polis, Minas Gerais, Brazil, 6Department of Infectious Disease, Faculty of Medicine, University of Sa˜o Paulo, Sa˜o Paulo, Brazil
Abstract
Background: Hepatitis C virus (HCV) infection is a global health problem estimated to affect almost 200 million people
worldwide. The aim of this study is to analyze the subtypes and existence of variants resistant to protease inhibitors and
their association with potential HCV risk factors among blood donors in Brazil.
Methods: Repeat anti-HCV reactive blood donors are systematically asked to return for retest, notification, and counseling in
which they are interviewed for risk factors for transfusion-transmitted diseases. We analyzed 202 donors who returned for
counseling from 2007 to 2010 and presented enzyme immunoassay- and immunoblot-reactive results. The HCV genotypes
and resistance mutation analyses were determined by the direct sequencing of the NS5b and NS3 regions, respectively. The
HCV viral load was determined using an in-house real-time PCR assay targeting the 59-NCR.
Results: HCV subtypes 1b, 1a, and 3a were found in 45.5%, 32.0%, and 18.0% of the donors, respectively. The mean viral
load of genotype 1 was significantly higher than that of the genotype 3 isolates. Subtype 1a was more frequent among
young donors and 3a was more frequent among older donors. Protease inhibitor-resistant variants were detected in 12.8%
of the sequenced samples belonging to genotype 1, and a higher frequency was observed among subtype 1a (20%) in
comparison to 1b (8%). There was no difference in the prevalence of HCV risk factors among the genotypes or drug-
resistant variants.
Conclusions: We found a predominance of subtype 1b, with an increase in the frequency of subtype 1a, in young subjects.
Mutations conferring resistance to NS3 inhibitors were frequent in treatment-naı¨ve blood donors, particularly those infected
with subtype 1a. These variants were detected in the major viral population of HCV quasispecies, have replicative capacities
comparable to nonresistant strains, and could be important for predicting the response to antiviral triple therapy.
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Introduction
HCV was identified by Choo et al. in 1989 [1] and is currently
a major cause of chronic hepatitis in the world, with almost 200
million carriers (2–3% of the global population) and approxi-
mately 350,000 deaths annually [2].
Blood transfusion, contaminated blood products, and unsafe
medical practices were the main routes of global HCV spread after
the Second World War until the early 1980s [3]. Although the
introduction of screening tests for blood donors reduced the risk of
transfusion-transmitted HCV [4], the use of illicit intravenous
drugs remains one of the major risk factors for HCV infection [5].
Sexual behavior can also be a minor risk factor for infection yet
can be an important route of transmission among intravenous
drug users (IVDUs), particularly men who have sex with other
men or prostitutes [6,7]. In Brazil, the prevalence of HCV
infection may reach 11% in IVDUs [8,9], is approximately 1.5%
in the general population [10–12], and ranges from 0.21% to
1.1% in blood donors [13–18]. Furthermore, HCV prevalence is
decreasing among blood donors, and de Almeida-Neto et al.
found a low HCV prevalence (0.19%) in three large Brazilian
blood centers in 2013, which could be due to improvements in
blood donor selection and in the social and economic conditions of
the population [19].
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HCV has a high genetic variability and is classified into seven
major genotypes and over 100 subtypes that vary with regard to
their geographic distribution, risk factors associated with infection,
and response to treatment [20–22]. The combination of pegylated
interferon alpha (IFN-a) (an important mediator of the innate
antiviral immune response) and ribavirin (a nucleoside analog that
acts on viral replication) was the standard treatment of patients
with chronic hepatitis C during many years [23,24]. Genotypes 1,
2, and 3 are widely distributed [21,25,26]; genotype 1 is the most
prevalent and also presents the worst response to antiviral therapy,
with only 40% of patients responding to this treatment [27,28].
Thus, in the search for more effective drugs, new direct-acting
inhibitors have recently been developed to inhibit the nonstruc-
tural protein (NS3/4) of genotype 1, a protease that is important
for the cleavage of the polyprotein during the viral replicative cycle
[29]. Two first-generation drugs, boceprevir and telaprevir, were
approved for use in the USA and Europe in 2011 [30–32] and
in Brazil is provided at no cost for the treatment of genotype
1-infected patients with advanced fibrosis or cirrhosis [33]. In
preliminary studies, these protease inhibitors alone induced the
rapid selection of resistant viral variants [34,35]; however, the
combination of these new drugs that inhibit the viral protease
(boceprevir or telaprevir) with INF-a and ribavirin (triple therapy)
showed an improvement in the sustained virological response
(SVR) rate of up to 75% [30,31,36–38].
Despite the success of direct-acting drugs, approximately 25%
of patients infected with genotype 1 do not achieve SVR [30,31].
During treatment, viral breakthrough can occur in approximately
2–7% of patients in whom there is the reappearance of HCV
RNA, mainly due to the emergence of higher-level resistant
variants, which explains the failure of therapy [30,39,40].
The variants associated with resistance are present prior to
therapy and are part of the quasispecies population in infected
individuals. These mutations, which do not alter viral fitness, may
occasionally be found in frequencies ranging from 2–29% in
untreated individuals [41–49]. The major reason for this wide
Figure 1. Flowchart summarizing the routine screening and confirmatory testing for HCV and the results of the genotyping and
protease inhibitor-resistance mutation analyses. Notes: EIA - Enzyme immunoassay (EIA); IB - Immunoblot assay.
doi:10.1371/journal.pone.0086413.g001
HCV Genotypes, Drug-Resistance and Risk Factors
PLOS ONE | www.plosone.org 2 January 2014 | Volume 9 | Issue 1 | e86413
variation in frequency depends on which genotype/subtypes are
studied and how the variants, as potential resistance mutations, are
defined. Indeed, baseline resistance variants can vary worldwide
from 14–29% in Europe to ,1–9% in the USA among patients
infected with subtype 1a, with V36L, T54S, V55A, Q80K, and
R155K as the main substitutions found. The frequency for subtype
1b in Japan was found to be 5%, in Europe from 10–25%, and
approximately 2% in the USA, with V36L and T54S as the
frequent mutations [43–46,48–50].
In this study, we analyzed HCV subtypes and the existence of
variants resistant to protease inhibitors and their association with
demographic and potential risk factors involved in the spread of
HCV in a group of Brazilian blood donors.
Materials and Methods
Ethics Statement
This project was approved by the Ethics Committee of the
Federal University of Sa˜o Paulo (UNIFESP)/Sa˜o Paulo Hospital
under protocol 1760/11. As a routine process of the blood bank,
donors sign an informed consent to allow the use of their samples
for quality control purposes. The study linked the routine
epidemiological data obtained during medical counseling with
the genotype and viral load data performed to characterize the
sample for the quality control department. The dataset and an
aliquot of the sample were anonymized for the data analysis and
drug resistance testing.
Study Population
From September 2007 to July 2011, a total of 570,600 blood
donors of Fundac¸a˜o Pro´- Sangue/Hemocentro de Sa˜o Paulo
(Brazil) were screened for HCV using a high-sensitivity enzyme
immunoassay (EIA) to detect antibodies, and 1,226 (0.21%)
samples were found to be reactive. Only 591 of these donors (48%)
returned for re-testing. The samples from donors with a reactive
result for the second EIA were subjected to an immunoblot assay
(IB). Of the 591 samples, 205 (35%) were confirmed positive for
HCV antibodies by immunoblotting, 264 (45%) were negative,
and 122 (20%) were inconclusive. Three samples had no sufficient
amount of serum and were withdrawn. Therefore, a total of 202
samples were included in this study (Figure 1). HCV antibodies
were screened using ORTHO HCV 3.0 (Biolab-Me´rieux S/A,
Rio de Janeiro, Brazil), and immunoblot CHIRON RIBA HCV
3.0 S/A (Chiron Corporation, Emeryville, EUA) was used for the
diagnostic confirmation.
As a part of the routine counseling process, the donors were
systematically asked about potential HCV risk factors involved in
transmission by blood transfusion, previous medical procedures,
such as surgeries and endoscopies, exposure to contamination
through tattooing, piercing, manicure, pedicure, or barber
procedures, intravenous drug use, occupational exposure, and
sexual behavior. These data were recorded in the information
system of the blood bank. Core demographic data, such as age,
sex, ethnicity, and education, were also recorded. The data were
extracted from the operation system and linked to the sample, and
the dataset was anonymized.
HCV Extraction, cDNA Synthesis, and Determination of
Viral Load
The quantitative assay to detect the HCV viral load was
performed by an in-house real-time PCR assay that amplified part
of the 59-NCR region (59 noncoding region) with a sensitivity of
approximately 400 IU/mL. Total RNA was extracted from
140 mL of plasma using the QIAamp Viral RNA Mini Kit
(Qiagen, Hilden, Germany) and eluted in 60 mL of elution buffer.
cDNA was obtained by a reverse transcriptase reaction using 10 mL
of the extracted RNA, 15 ng/mL of random primer (Amersham
Biosciences, Piscataway, NJ, USA), and 10 U/mL of Super Script
TM III reverse transcriptase (Invitrogen, Carlsbad, CA, USA) in a
buffer containing 0.25 U/mL of ribonuclease inhibitor (Invitrogen,
Carlsbad, CA, USA) and 0.5 mM deoxyribonucleotide triphos-
phates (Invitrogen, Carlsbad, CA, USA) (final volume of 20 mL).
The reaction was incubated at 45uC for 90 minutes. The cDNA
(5 mL) was added to 20 mL of TaqMan Master Mix (Applied
Biosystems, Foster, CA, USA) and amplified by real-time PCR
using the following primers and probe: HCV_sense, 59CGTC-
TAGCCATGGCGTAAGTA39; HCV_anti-sense, 59GGTTCCG-
CAGACCACTATGG39; HCV_Probe, 59FAM-CCCCCCTCC-
CGGGAGA-NFQ-39. The reaction was performed using the
StepOne system (Applied Biosystems, Foster, CA, USA) for 45–50
cycles with the following program: 10 minutes at 95uC, followed by
45 cycles of 15 seconds for 94uC and 60 seconds at 60uC.
HCV Phylogenetic Analysis and Genotyping
Only samples with a detectable viral load were subjected to
nested PCR to amplify a 400-bp fragment from the non-structural
region 5B (NS5B) gene, including part of the RNA-dependent
RNA polymerase, using previously described PCR primers and
conditions [51,52]. The PCR product was purified using the
QIAquick kit (QIAGEN, Hilden, Germany) and directly se-
quenced using the Big Dye Terminator Cycle Sequencing Ready
Reaction (Applied Biosystems, Foster City, USA) according to the
manufacturer’s procedure.
The sequences were edited using the SEQUENCHER program
(Gene Codes Corporation Ann Arbor, MI, USA) and aligned with
the reference sequences of the six main genotypes obtained from
GenBank in Bioedit [53]. The phylogenetic analysis was
performed using the PHYLIP 3.5c program [54]. Bootstrap values
were determined on 1000 replicates of the sequence data with the
SEQBOOT program (PHYLIP 3.5c). The phylogenetic relation-
ships were constructed using the neighbor-joining method, and the
pairwise distances were calculated by DNADIST (PHYLIP 3.5c).
A consensus tree was identified using the CONSENSE program
(PHYLIP 3.5c).
Genotype confirmation was performed using available online
tools at the following sites: (http://www.bioafrica.net/
regagenotype/html/subtypinghcv.html) and (http://www.ncbi.
nlm.nih.gov/projects/genotyping/formpage.cgi).
The HCV sequences were deposited in GenBank under
accession numbers KF523955–KF524257.
Analysis of Mutations Associated with Resistance to
Protease Inhibitors
All the genotype 1 samples were subjected to nested or semi-
nested PCR to amplify the region encoding the non-structural
region 3 (NS3) protease catalytic domain [34,55,56] and
sequenced as described above. Predictions of the phenotypic
resistance of the NS3 region to boceprevir and telaprevir were
determined using the online tool geno2pheno [hcv] (http://hcv.
bioinf.mpi-inf.mpg.de/index.php) [56,57]. This algorithm consid-
ers amino acid substitutions associated with resistance observed in
clinical trials (V36A/G/L/M, Q41R/K/P, F43C/S/L, T54A/S,
V55A, Q80R/K, R109K, R155K/T/G/I/M/S, A156S/T/V,
and V170A/T/G) [49,58–61] and others rarely reported in vivo
(A87T, R117H, N174F, and S138T/D) [62]. For a ‘next-
generation’ drug (simeprevir), the sequences were aligned with a
reference in Bioedit [53], and the amino acid mutations were
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Table 1. HCV genotype distribution according donor demographics, risk factors, and HCV viral load.
Subtype (%)
Characteristics Subcategory 1a n=57 1b n=81 3a n=32 Others n=8 p-value
Sex Male 29 (28.7) 51 (50.5) 18 (17.8) 3 (3.0) 0.45*
Female 28 (36.4) 30 (39.0) 14 (18.2) 5 (6.4)
Age 18–29 y 19 (42.2) 17 (37.8) 7 (15.5) 2 (4.5) 0.047*
30–39 y 15 (26.8) 34 (60.7) 6 (10.7) 1 (1.8)
40–49 y 16 (35.6) 17 (37.8) 11 (24.4) 1 (2.2)
.50 y 7 (21.9) 13 (40.6) 8 (25.0) 4 (12.5)
Ethnicity Mulatto 7 (26.9) 16 (61.5) 2 (7.7) 1 (3.9) 0.39*
Pardo 22 (32.8) 30 (44.8) 13 (19.4) 2 (3.0)
White 27 (35.2) 31 (40.3) 14 (18.2) 5 (6.5)
Asian 0 (0.0) 1 (50.0) 1 (50.0) 0 (0.0)
Missing 1 3 2 0
Education ,8 y 7 (20.6) 16 (47.1) 8 (23.5) 3 (8.8) 0.77*
Completed 8 y 8 (42.1) 8 (42.1) 3 (15.8) 0 (0.0)
11 y 33 (37.9) 38 (43.7) 13 (14.9) 3 (3.5)
Technical college 2 (40.0) 2 (40.0) 1 (20.0) 0 (0.0)
University course 6 (24.0) 13 (52.0) 4 (16.0) 2 (8.0)
Missing 1 4 3 0
Blood transfusion Yes 5 (25.0) 8 (40.0) 7 (35.0) 0 (0.0) 0.26*
No 52(32.9) 73(46.2) 25 (15.8) 8 (5.1)
Tattoo Yes 11 (34.4) 14 (43.7) 4 (12.5) 3 (9.4) 0.81*
No 36 (30.0) 54 (45.0) 25 (20.8) 5 (4.2)
Missing 10 13 3 0
Occupational exposure Yes 4 (44.4) 4 (44.4) 1 (11.2) 0(0.0) 0.57*
No 46 (31.3) 65 (44.2) 28 (19.1) 8 (5.4)
Missing 7 12 3 0
Sex partner of IVDU Yes 0 (0.0) 5 (83.3) 1 (16.7) 0 (0.0) 0.050*
No 45 (31.0) 64 (44.2) 28 (19.3) 8 (5.5)
Missing 12 12 3 0
Sex partner of hepatitis+ individual Yes 1 (33.4) 1 (33.3) 0 (0.0) 1 (33.3) 0.49*
No 48 (31.6) 68 (44.7) 29 (19.1) 7 (4.6)
Missing 8 12 3 0
Have given or received
money or drugs for sex
Yes 4 (20.0) 10 (50.0) 5 (25.0) 1 (5.0) 0.77*
No 46 (33.8) 59 (43.4) 24 (17.6) 7 (5.2)
Missing 7 12 3 0
UDIV Yes 2 (20.0) 7 (70.0) 0 (0.0) 1 (10.0) 0.37*
No 48 (33.1) 62 (42.8) 28 (19.3) 7 (4.8)
Missing 7 12 4 0
HBV+ or HCV+ relatives Yes 5 (19.3) 15 (57.7) 3 (11.5) 3 (11.5) 0.10*
No 45 (34.6) 54 (41.5) 26 (20.0) 5 (3.9)
Missing 7 12 3 0
HCV RNA (log10 UI/mL) mean Mean 5.99 6.35 5.22 6.64
Subtype 3a vs 1a 0.0002**
Subtype 3a vs 1b 0.0000**
*Pearson’s chi-squared test.
**Tukey’s t test.
doi:10.1371/journal.pone.0086413.t001
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manually verified (V36M, F43S, T54S, Q80K/R/L, S122A/R,
S138T, R155K, A156TV, and D168A/V/E/H/T) [62].
Statistical Analysis
The characteristics were evaluated according to the genotype or
resistance profile of the patients. A chi-square test was used to
compare the proportions at a 95% significance level. Tukey’s t test
was used to compare the means.
Results
Among 202 HCV-positive samples from blood donors, 88%
(178/202) were positive for HCV RNA and showed the following
viral load distribution: 3.4% (6/178) with viral loads between 400
and 9,999 IU/mL, 11.8% (21/178) between 10,000 and
99,999 IU/mL, 29.8% (53/178) between 100,000 and
999,999 IU/mL, and 55.0% (98/178) with.1,000,000 IU/mL.
A total of 12% (24/202) of donors had an undetectable viral load.
The HCV genotypes were determined by NS5b amplification,
and sequencing was successful in all 178 RNA-detectable samples;
of these, 45.5% (81/178) were typed as 1b, 32.0% (57/178) as 1a,
18.0% (32/178) as 3a, and 4.5% (8/178) as others (2b (5/8), 2c (1/
8), 4 (1/8), and 5 (1/8)) (figure 1).
The genotypes were not associated with gender, ethnicity, or
educational level; however, subtype 1a was more frequently found
among young donors, 1b among the intermediate age group, and
subtype 3a among older donors (p = 0.047) (Table 1). Viral load
was not associated with gender or age, but genotype 3a (5.22 log10
IU/mL) had a lower log mean than genotype 1a (5.99 log10 IU/
mL) (3a vs 1a, p = 0.0002) and genotype 1b (6.35 log10 IU/mL) (3a
vs 1a; p = 0.0000) (Table 1). There was no difference in the
prevalence of all risk factors among the different genotypes, despite
the high frequency of donors that cited the following: previous
blood transfusion, 11.2% (20/178); intravenous drug use, 6.4%
(10/155); and have given or received money or drugs for sex,
12.8% (20/156).
We found that 19.1% (34/178) of the donors reported no
known risk factors associated with infection; 19.1% (34/178)
reported only one potential parenteral or sexual exposure, 32.0%
(57/178) reported two factors, and 29.8% (53/178) reported three
or more (multiple) risk factors.
Only the genotype 1 samples were analyzed by amplification
and sequencing of the region encoding the NS3 viral protease,
which was successful in 90.6% (125/138) or 88.0% (50/57) cases
of subtype 1a and 93.0% (75/81) cases of subtype 1b. The results
of genotyping by phylogenetic analysis or online analysis tools
assigned the same genotype.
The frequency of blood donors with a resistance-associated
variant was 10.4% (13/125) for boceprevir, 11.2% (14/125) for
telaprevir, and 6.4% (8/125) for simeprevir, for a total of 16/125
(12.8%) for all three protease inhibitors (Table 2).
Drug-associated mutations were found at a higher frequency in
individuals infected with subtype 1a (20%) than subtype 1b (8%)
(p = 0.02) (Table 3). The frequency of mutations associated with
protease inhibitor resistance was 20% (10/50) among the subtype
1a isolates, with the following changes: [(2x) V36L, (3x) V55A, (1x)
Q80L, and (5x) R155K]. For subtype 1b, the frequency of these
mutations was 8% (6/75), with the following substitutions: [(2x)
T54S, (1x) V55A, (2x) R117H, and (1x) D168G]. The most
prevalent mutation, R155K, was found in 4.0% (5/125) of all the
sequences or 10% (5/50) of the subtype 1a sequences.
There was no association of drug resistance with sex, ethnicity,
education level, age, or any risk factor. In addition, no difference
in the log mean viral load between the resistant variants and wild
Table 2. Amino acid substitutions and frequency of blood donors with mutations conferring resistance to protease inhibitors.
Sample no Subtype Mutation Resistance
6 1a V55A Boceprevir/Telaprevir
32 1a R155K Boceprevir/Telaprevir/Simeprevir
33 1b R117H Boceprevir/Telaprevir
44 1a R155K Boceprevir/Telaprevir/Simeprevir
54 1b D168G Boceprevir
55 1a V36L/V55A Boceprevir/Telaprevir
62 1a R155K Boceprevir/Telaprevir/Simeprevir
63 1b T54S Telaprevir/Simeprevir
64 1a Q80L Low Simeprevir
70 1b R117H Boceprevir/Telaprevir
93 1a R155K Boceprevir/Telaprevir/Simeprevir
107 1a V55A Boceprevir/Telaprevir
110 1a V36L Boceprevir/Telaprevir
127 1b V55A Boceprevir/Telaprevir
134 1b T54S Telaprevir/Simeprevir
184 1a R155K Boceprevir/Telaprevir/Simeprevir
Total
frequency
16/125 (12.8%)
Boceprevir 13/125 (10.4%)
Telaprevir 14/125 (11.2%)
Simeprevir 8/125 (6.4%)
doi:10.1371/journal.pone.0086413.t002
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Table 3. Frequency of blood donors with mutations conferring resistance to protease inhibitors according to demographics, risk
factors, subtypes, and HCV viral load.
Total n =125 N (%) of resistance n=16 p-value
Sex Male 75 9 (12.0) 0.37*
Female 50 7 (14.0)
Age 18–29 y 33 5 (15.2) 0.30*
30–39 y 45 4 (8.9)
40–49 y 28 6 (21.4)
.50 y 19 1 (5.3)
Ethnicity Pardo 68 8 (11.8) 0.90*
White 53 7 (13.2)
Asian 1 0 (0.0)
Missing 3 1
Education ,8 years 20 1 (5.0) 0.58*
Completed 8 Years 16 3 (18.8)
11 years 66 8 (12.1)
Technical college 3 1 (33.3)
University course 16 2 (12.5)
Missing 4 1
Blood transfusion Yes 13 1 (7.7) 0.28*
No 112 15 (13.4)
Tattoo Yes 25 1 (4.0) 0.10*
No 78 10 (12.8)
Missing 22 5
Occupational exposure Yes 5 1 (20.0) 0.29*
No 101 12 (11.9)
Missing 19 3
Sex partner of blood transfusion recipient Yes 2 1 (50.0) 0.05*
No 103 12 (11.6)
Missing 20 3
Condom use Yes 36 4 (11.1) 0.33*
No 64 9 (14.1)
Missing 25 3
Have given or received
money or drugs for sex
Yes 13 2 (15.4) 0.35*
No 93 11 (11.8)
Missing 19 3
IVDU Yes 9 1 (11.1) 0.45*
No 97 12 (12.2)
Missing 19 3
HBV+ or HCV+ relatives Yes 19 4 (21.1) 0.09*
No 87 9 (10.3)
Missing 19 3
HCV Subtype 1a 50 10 (20.0) 0.02*
1b 75 6 (8.0)
HCV RNA (log 10 UI/mL) mean Resistant variant 6.06 0.8485**
Wild type 6.32
*Pearson;s chi-squared test.
**Tukey’s t test.
doi:10.1371/journal.pone.0086413.t003
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type was observed (6.06 log10 IU/mL vs 6.32 log10 IU/mL,
p = 0.8485) (Table 2). Moreover, drug resistance could not be
associated with any risk factor (Table 3).
Discussion
HCV subtype 1b was the most prevalent subtype in our studied
blood donors and was found in almost half of the cases, followed
by subtypes 1a and 3a. We also found such rare genotypes as 2b,
2c, 4, and 5 at very low frequencies. These data are in agreement
with Brazilian studies that have shown a predominance of subtype
1a or 1b, followed by 3 in patients from the state of Sa˜o Paulo
[63–65].
Most donors exhibited a very high viral load. When analyzing
the viral load according to the subtype distribution, subtype 3a
presented a lower mean viral load than subtypes 1a and 1b.
Previous studies have also described an association between
genotype 1 and higher levels of HCV-RNA in the serum of
infected patients compared to those infected with genotypes 2 and
3 [66–68]. Viral load was undetectable in 12% of the donors, and
half of them were female. It is known that spontaneous viral
clearance may occur in approximately 25% of HCV infections,
mainly in women and some ethnic groups in association with the
favorable genotype of the IL28B gene [69–71].
The genotype distribution according to age showed that subtype
1a was more frequent among younger donors and subtype 3a in
donors older than 40 years. This result differs in part from another
study also performed in Sa˜o Paulo that reported that subtypes 1a
and 3a appear to be more associated with newly infected young
people and possibly with a higher rate of sexual transmission [65].
Both genotypes were also associated with IVDUs [72,73] and
presented a high prevalence in this group, reaching 60% for
subtype 1a and 20% for 3 [8,74]. Moreover, Vigani et al. [75]
reported an association between genotype 3 and the non-illicit IV
drug Gluconergan, which was commonly used in the 1970s in Sa˜o
Paulo as a stimulant. Indeed, Gluconergan users shared needles
and syringes, and the IV route might explain the high frequency of
HCV genotype 3 among older blood donors.
Subtype 1b began to spread 40–60 years earlier than subtype
1a. The spread of subtype 1b has been associated with blood
transfusions during the 1940s until the 1980s and affected a wide
age range [76], which explains the high frequency of this subtype
in the intermediate age group of our donors. Despite being the
most prevalent in our population, subtype 1b has shown a slower
growth rate than genotypes 1a and 3a [65], and perhaps a change
in the prevalence in the predominant genotype may occur in
Brazil, as has been verified in the USA and Europe [77,78]. The
probable hypothesis is that the introduction of new subtypes in
high-risk groups may rapidly impact lower-risk groups by an
increasing prevalence in the general population [78].
There was no association of any genotype with potential HCV
risk factors, such as IVDU, blood transfusion, or sexual behavior.
This finding suggests that risk factors for HCV transmission are
still unknown in our population or that different genotypes are
disseminating through different transmission routes in blood
donors. Approximately 80% of the infected patients mentioned
at least one HCV risk factor, whereas 20% of the donors did not
disclose any risk factor. A large proportion of donors had multiple
risk factors associated with HCV transmission, and it is possible
that the sum of several factors may be contributing to the spread of
the virus. In our study, a single individual reported tattooing,
piercing, surgery, endoscopy, transfusion, manicure, and highly
risky sexual behavior, which depicts a common scenario in our
current society.
After mandatory screening for anti-HCV antibodies, the risk of
transmission by blood transfusions has decreased markedly and is
currently very low (5/1,000,000 units transfused) [19], similar to
the incidence in some locations in Europe and the USA.
Nonetheless, measures to prevent HCV transmission among drug
users are needed and also in medical and paramedical practices. In
addition, special attention to high-risk sexual behavior among
UDIV infected or co-infected with HIV is warranted.
Brazilian studies have found frequencies of between 3.2% and
18.9% of patients with variants associated with resistance among
HCV chronic carriers not treated with protease inhibitors
[41,42,79]. Our data showed an intermediate total frequency of
resistance when compared to other results found in Brazil.
Among the genotype 1a-infected Brazilian donors, we observed
the mutations V36L (4%) and V55A (6%), which confer a low
level of resistance at frequencies close to those found the USA
(1–2% for V36M) and Europe (3–6% for V36L and V55A)
[44–46,48–50]. In contrast, a prevalence different from that found
in other studies was identified for two mutations, Q80K and
R155K, which confer moderate-level resistance. The Q80K
mutation, which is associated with resistance to simeprevir and
is very common in the USA (40%) [50] and Europe (4–16%)
[45,46], was not found in our study. Another important
observation was that the R155K mutation has a low prevalence
in the USA (1%) [48–50] but was found in 10% of the untreated
individuals in our population. These findings could be related to
certain Brazilian 1a subtypes, and it appears that the Brazilian
sequences have their own pattern of mutations and frequencies,
which differ from other parts of the world.
Next-generation drugs have been developed to be effective in
different genotypes and have a higher genetic barrier to resistance
than first-generation drugs [62] Indeed, we observed a lower
frequency of baseline variants resistant to simeprevir (6%) than
boceprevir (10%) and telaprevir (11%), and these data could help
in future treatment choices for the Brazilian population.
The genetic barrier for resistance to protease inhibitors may also
vary according to different HCV subtypes. The frequency of
resistance mutations was twice as high among patients with
subtype 1a compared to those with subtype 1b. An amino acid
substitution at position R155K requires only a single nucleotide
change (a transition) to confer resistance, whereas mutation for
subtype 1b requires two nucleotide changes, one of which must be
a transversion [80]. Pawlotsky et al. [59] reported a higher
frequency of virologic failure for subtype 1a due to the lower
genetic barrier to viral resistance than for subtype 1b. The R155K
mutation also confers cross-resistance to all protease inhibitors
though does not modify the fitness of the strains that carry this
mutation. Our study showed no difference between the viral loads
of resistance or sensitivity of the strains, confirming that both have
comparable replicative capacities. We should emphasize that, as
the classical sequencing techniques can identify the major viral
population, the variants detected could be important with regard
to treatment failure.
In summary, we report a predominance of subtype 1b, with an
increase in the frequency of subtype 1a in younger donors. Rare
genotypes, such as 2b, 2c, 4, and 5, were also found. HCV
subtypes 1a and 1b showed higher viral loads than subtype 3a. We
failed to associate any genotype to potential HCV risk factors;
known risk factors explained 80% of the infected cases, but 20% of
the donors did not report any of the risk factors examined.
Regardless, the majority of donors reported more than one risk
factor for HCV infection. Thus, blood banks must be encouraged
to increase notification and counseling measures for these donors
to prevent the spread of HCV. Mutations conferring resistance to
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NS3 inhibitors were frequent in treatment-naı¨ve blood donors but
could not be associated with any risk factor. The presence of these
mutations in the major population of HCV quasispecies that have
replicative capacities comparable to nonresistant strains could be
important for predicting response to antiviral triple therapy.
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